Glaxo Antibody Works Against Omicron Variant

Sam Fazeli discusses the effectiveness of Glaxo's vaccine against variants, particularly Omicron. He explains how monoclonal antibodies work by coating the virus, and the challenges posed by mutations. The role of T cells in immunity, especially post-vaccination, is highlighted. The conversation also covers new vaccines, including GSK's involvement, and the logistics of vaccine distribution, emphasizing the importance of ease in transportation and storage.

What is the reported efficacy of Glaxo's vaccine against hospitalization for the Omicron variant?

• 90-100%

• 50-60%

• 70-80%

• 60-70%

How do monoclonal antibodies help in fighting the virus?

• By increasing the body's temperature

• By enhancing T cell production

• By coating the virus to prevent cell infection

• By destroying the virus directly

What is a potential issue with monoclonal antibodies when the virus mutates?

• They become more effective

• They lose their ability to coat the virus

• They increase the virus's strength

• They cause severe side effects

What is one advantage of the new vaccines being developed?

• They are less effective

• They are more expensive

• They have a shorter shelf life

• They do not require refrigeration

What is the benefit of mixing and matching different vaccines?

• It reduces the number of doses needed

• It potentially increases the effectiveness of the booster

• It causes fewer side effects

• It eliminates the need for boosters